How to buy Immunomedics stock

Immunomedics, Inc is a biotechnology business based in the US. Immunomedics shares (IMMU) are listed on the NASDAQ and all prices are listed in US Dollars. Immunomedics employs 366 staff and has a trailing 12-month revenue of around USD$20.4 million.

How to buy shares in Immunomedics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Immunomedics. Find the stock by name or ticker symbol: IMMU. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immunomedics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Immunomedics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Immunomedics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Immunomedics share price

Use our graph to track the performance of IMMU stocks over time.

Immunomedics shares at a glance

• Key figures

Information last updated 2020-10-20.

52-week range	USD$8.8 - USD$87.68
50-day moving average	USD$74.5437
200-day moving average	USD$44.7741
Wall St. target price	USD$75.62
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.631

Buy Immunomedics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Immunomedics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Immunomedics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunomedics financials

Revenue TTM	USD$20.4 million
Gross profit TTM	USD$-254,576,000
Return on assets TTM	-25.16%
Return on equity TTM	-100.04%
Profit margin	0%
Book value	$2.569
Market capitalisation	USD$20.3 billion

TTM: trailing 12 months

Shorting Immunomedics shares

There are currently 23.6 million Immunomedics shares held short by investors – that's known as Immunomedics's "short interest". This figure is 11.4% down from 26.6 million last month.

There are a few different ways that this level of interest in shorting Immunomedics shares can be evaluated.

Immunomedics's "short interest ratio" (SIR)

Immunomedics's "short interest ratio" (SIR) is the quantity of Immunomedics shares currently shorted divided by the average quantity of Immunomedics shares traded daily (recently around 8.3 million). Immunomedics's SIR currently stands at 2.85. In other words for every 100,000 Immunomedics shares traded daily on the market, roughly 2850 shares are currently held short.

However Immunomedics's short interest can also be evaluated against the total number of Immunomedics shares, or, against the total number of tradable Immunomedics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunomedics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Immunomedics shares in existence, roughly 100 shares are currently held short) or 0.1143% of the tradable shares (for every 100,000 tradable Immunomedics shares, roughly 114 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunomedics.

Find out more about how you can short Immunomedics stock.

Immunomedics share dividends

We're not expecting Immunomedics to pay a dividend over the next 12 months.

Have Immunomedics's shares ever split?

Immunomedics's shares were split on a 2:1 basis on 24 June 1985. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Immunomedics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Immunomedics shares which in turn could have impacted Immunomedics's share price.

Immunomedics share price volatility

Over the last 12 months, Immunomedics's shares have ranged in value from as little as $8.8 up to $87.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunomedics's is 2.9018. This would suggest that Immunomedics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Immunomedics overview

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Frequently asked questions

• What percentage of Immunomedics is owned by insiders or institutions?

  Currently 0.137% of Immunomedics shares are held by insiders and 81.313% by institutions.

• How many people work for Immunomedics?

  Latest data suggests 366 work at Immunomedics.

• When does the fiscal year end for Immunomedics?

  Immunomedics's fiscal year ends in December.

• Where is Immunomedics based?

  Immunomedics's address is: 300 The American Road, Morris Plains, NJ, United States, 07950

• What is Immunomedics's ISIN number?

  Immunomedics's international securities identification number is: US4529071080

• What is Immunomedics's CUSIP number?

  Immunomedics's Committee on Uniform Securities Identification Procedures number is: 452907108